Nuestros blogs explican las afecciones de salud y la investigación clínica de una manera fácil de entender, para que los lectores se sientan más informados.
El medicamento Antabuse contra el abuso del alcohol mata las células cancerosas.
A new study of Alcohol-abuse Drug Antabuse is effective against cancer cells. The study has researched by an international team including researchers from Karolinska Institutet. The study also identifies a potential mechanism of action for the anti-tumor effect. As developing new cancer...
Los cromosomas podrían revelar una relación con el síndrome de Down y otras enfermedades
The centromere is the structure at the center of every X-shaped chromosome, where cells attached the long, thin spindles that pull the two copies of DNA apart during cell division. A new technique makes it much easier for centromere research, and...
Cell-based Therapy for Type 1 Diabetes?
Cell-based Therapy for Type 1 Diabetes has been studied by researchers at Boston Children’s Hospital has successfully reversed type 1 diabetes in a mouse model by infusing blood stem cells pre-treated to produce more of a protein called PD-L1, which is...
El tratamiento contra los parásitos combate el cáncer de próstata
Cancer researchers at the University of Bergen (UiB) in Norway have been experimenting with hundreds of known drugs in recent years to see how they influence cancer cells of Prostate Cancer. Their most recent discovery shows that a medication prescribed for...
La FDA aprueba la primera pastilla digital para trastornos psiquiátricos
The U.S. Food and Drug Administration (FDA) made the first approval of a drug imbued with a digital ingestion tracking system.The treatment is called Abilify MyCite, which is intended to treat schizophrenia, acute treatment of manic and mixed episodes associated with...
Scientists Discover Potential Treatment to Stop Glaucoma in its Tracks
Vision scientists at UC Berkeley and the University of Toronto have discovered that naturally occurring molecules known as lipid mediators have the potential to halt the progression of glaucoma, the world’s second-leading cause of blindness. Their findings, published today...
Statement from FDA Commissioner
Today the Administration took a historic step to direct additional resources to help address the staggering human and economic toll created by the epidemic of opioid addiction. We thank President Trump for his leadership in further empowering public and private parties...
Erytech Unveils New Data for Pancreatic Cancer Combination Therapy
A French biotech firm testing a unique treatment approach for metastatic pancreatic cancer reported promising mid-stage results for its lead candidate. Erytech Pharma evaluated eryaspase (Graspa), an enzyme called L-asparaginase encapsulated in red blood cells, in combination with chemotherapy as a...
Zika Virus Kills Brain Cancer Stem Cells
While Zika virus causes devastating damage to the brains of developing fetuses, it one day may be an effective treatment for glioblastoma, a deadly form of brain cancer. New research from Washington University School of Medicine in St. Louis and the...
Study: Asthma Medicine Halves Parkinson’s Risk
Parkinson’s disease is a chronic disease of unknown cause. The patients destroy the cells in the brain that help control movement. Typical symptoms are tremors, stiffness in the arms and legs, and poor coordination. This limits the ability to participate in everyday...
Anti-Inflammatory Drug Reduces Heart Attack, Cancer Risk
About 25 percent of heart attack patients will experience another cardiovascular event within five years, even if they do not have high cholesterol heart attack recurrence is present. Researchers at Brigham and Women’s hospital in Boston have shown that lowering inflammation,...
5 ways to boost Minorities’ Participation in Clinical Trials
Minorities’ participation in clinical trials is often an issue of debate among the clinical research industry. Anyway, most of us agree that their participation is crucial in order to develop better treatments for everybody. That’s why as part of the professionals...